GoKawiilNovo Nordisk and Eli Lilly data suggest GLP-1 drugs slow molecular aging markers
New data from Novo Nordisk and Eli Lilly indicates that GLP-1 medications, the class that includes Ozempic, may slow biological aging as measured by molecular aging clocks. These clocks track chemical changes in cells believed to correlate with the pace of aging.